Cellectis S.A. (CLLS)
| Market Cap | 89.44M -65.9% |
| Revenue (ttm) | 63.82M +0.6% |
| Net Income | -65.31M |
| EPS | -0.64 |
| Shares Out | 72.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,665 |
| Open | 1.220 |
| Previous Close | 1.260 |
| Day's Range | 1.150 - 1.230 |
| 52-Week Range | 0.881 - 5.450 |
| Beta | 2.91 |
| Analysts | Buy |
| Price Target | 4.83 (+312.82%) |
| Est. Earnings | Nov 10, 2026 |
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with... [Read more]
Financial Performance
In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CLLS stock is "Buy." The 12-month stock price target is $4.83, which is an increase of 312.82% from the latest price.
News
Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Cellectis announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia, at the Annual Congress of the...
Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27
(RTTNews) - Cellectis S.A. (CLLS) on Tuesday reported expanded preclinical data showing its gene-editing candidate, .HEAL-101 reduced triglyceride levels in a mouse model of severe hypertriglyceridemi...
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of tr...
Cellectis sees FY27 adjusted EPS $21.50
Sees FY27 revenue $40B, consensus $35.71B. The company said, “We are also pleased to provide our initial 2027 annual outlook, with revenue of $40.0 billion, up 90%, record adjusted operating…
Cellectis sees FY27 capital expenditures $1.5B-$2B
The company said, “We continue to pursue investment plans in support of anticipated multi-year growth, supported by 2028 customer demand forecasts that are meaningfully higher than our 2027 revenue ou...
Cellectis sees Q4 adjusted EPS $3.37-$3.57
Sees Q4 revenue $6.28B-$6.58B, consensus $6.4B. Sees Q4 adjusted operating margin 8.7%.
Cellectis raises FY26 adjusted EPS view to $11.55 from $11.30, consensus $11.15
Raises FY26 revenue view to $21B from $20.5B, consensus $20.61B. Cuts FY26 free cash flow view to $460M from $600M. The company said, “Driven by these strong results to date…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to co...
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. (“Cellectis” o...
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors conce...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through one-t...
Cellectis Transcript: Stifel 2026 Virtual Cardiometabolic Forum
The forum highlighted a strategic shift to in vivo gene editing, advancing two lead programs targeting APOC3 and PCSK9 for severe lipid disorders. Preclinical data show strong efficacy, with first-in-human trials set for 2027–2028 and a focus on durable, one-time therapies for large, underserved populations.
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CLLS--CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law.
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) complied with federal securities laws. On Septemb...
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cellectis S.A. (“Ce...
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors concerning the Company'...
Cellectis downgraded to Underweight from Overweight at Barclays
Barclays analyst Lukas Shumway double downgraded Cellectis (CLLS) to Underweight from Overweight with a price target of $1.30, down from $9. Cellectis’ strategic shift and move back to a preclinical…
Cellectis price target lowered to $8 from $10 at Baird
Baird lowered the firm’s price target on Cellectis (CLLS) to $8 from $10 and keeps an Outperform rating on the shares. The fim updated its model as the company pivots…
Cellectis price target lowered to $3 from $4 at Wells Fargo
Wells Fargo analyst Nick Abbott lowered the firm’s price target on Cellectis (CLLS) to $3 from $4 and keeps an Equal Weight rating on the shares. The firm notes the…
Cellectis downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Cellectis (CLLS) to Market Perform from Outperform without a price target The company announced a major change to its strategy, halting further development of allogeneic CAR T cell...
Cellectis Transcript: Investor update
A strategic pivot shifts focus to in vivo gene editing, advancing .HEAL-101 and .HEAL-201 for severe lipid disorders with durable, one-time therapies. Internal cell therapy programs are discontinued, partnerships remain intact, and cash runway extends into 2028.
Cellectis Press release: Investor update
Cellectis issued a press release on September 14, 2026, disclosing material business information to investors.